These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38253179)

  • 1. Glioblastoma Pseudoprogression Discrimination Using Multiparametric Magnetic Resonance Imaging, Principal Component Analysis, and Supervised and Unsupervised Machine Learning.
    Thenier-Villa JL; Martínez-Ricarte FR; Figueroa-Vezirian M; Arikan-Abelló F
    World Neurosurg; 2024 Mar; 183():e953-e962. PubMed ID: 38253179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiation of Pseudoprogression from True Progressionin Glioblastoma Patients after Standard Treatment: A Machine Learning Strategy Combinedwith Radiomics Features from T
    Sun YZ; Yan LF; Han Y; Nan HY; Xiao G; Tian Q; Pu WH; Li ZY; Wei XC; Wang W; Cui GB
    BMC Med Imaging; 2021 Feb; 21(1):17. PubMed ID: 33535988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
    Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
    BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma.
    Kebir S; Khurshid Z; Gaertner FC; Essler M; Hattingen E; Fimmers R; Scheffler B; Herrlinger U; Bundschuh RA; Glas M
    Oncotarget; 2017 Jan; 8(5):8294-8304. PubMed ID: 28030820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of pseudoprogression in post-treatment glioblastoma using dynamic susceptibility contrast-derived oxygenation and microvascular transit time heterogeneity measures.
    Park JE; Kim HS; Kim N; Borra R; Mouridsen K; Hansen MB; Kim YH; Hong CK; Kim JH
    Eur Radiol; 2024 May; 34(5):3061-3073. PubMed ID: 37848773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
    Wick W; Chinot OL; Bendszus M; Mason W; Henriksson R; Saran F; Nishikawa R; Revil C; Kerloeguen Y; Cloughesy T
    Neuro Oncol; 2016 Oct; 18(10):1434-41. PubMed ID: 27515827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histopathology-validated machine learning radiographic biomarker for noninvasive discrimination between true progression and pseudo-progression in glioblastoma.
    Akbari H; Rathore S; Bakas S; Nasrallah MP; Shukla G; Mamourian E; Rozycki M; Bagley SJ; Rudie JD; Flanders AE; Dicker AP; Desai AS; O'Rourke DM; Brem S; Lustig R; Mohan S; Wolf RL; Bilello M; Martinez-Lage M; Davatzikos C
    Cancer; 2020 Jun; 126(11):2625-2636. PubMed ID: 32129893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shape Features of the Lesion Habitat to Differentiate Brain Tumor Progression from Pseudoprogression on Routine Multiparametric MRI: A Multisite Study.
    Ismail M; Hill V; Statsevych V; Huang R; Prasanna P; Correa R; Singh G; Bera K; Beig N; Thawani R; Madabhushi A; Aahluwalia M; Tiwari P
    AJNR Am J Neuroradiol; 2018 Dec; 39(12):2187-2193. PubMed ID: 30385468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different diagnostic values of imaging parameters to predict pseudoprogression in glioblastoma subgroups stratified by MGMT promoter methylation.
    Yoon RG; Kim HS; Paik W; Shim WH; Kim SJ; Kim JH
    Eur Radiol; 2017 Jan; 27(1):255-266. PubMed ID: 27048531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stratification of pseudoprogression and true progression of glioblastoma multiform based on longitudinal diffusion tensor imaging without segmentation.
    Qian X; Tan H; Zhang J; Zhao W; Chan MD; Zhou X
    Med Phys; 2016 Nov; 43(11):5889. PubMed ID: 27806598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preradiotherapy MR Imaging: A Prospective Pilot Study of the Usefulness of Performing an MR Examination Shortly before Radiation Therapy in Patients with Glioblastoma.
    Majós C; Cos M; Castañer S; Pons A; Gil M; Fernández-Coello A; Macià M; Bruna J; Aguilera C
    AJNR Am J Neuroradiol; 2016 Dec; 37(12):2224-2230. PubMed ID: 27609621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation of progressive disease from pseudoprogression using MRI histogram analysis in patients with treated glioblastoma.
    Yildirim M; Baykara M
    Acta Neurol Belg; 2022 Apr; 122(2):363-368. PubMed ID: 33555560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between the Prebolus T1 Measurement and the Fixed T1 Value in Dynamic Contrast-Enhanced MR Imaging for the Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Concurrent Radiation Therapy and Temozolomide Chemotherapy.
    Nam JG; Kang KM; Choi SH; Lim WH; Yoo RE; Kim JH; Yun TJ; Sohn CH
    AJNR Am J Neuroradiol; 2017 Dec; 38(12):2243-2250. PubMed ID: 29074633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients.
    Kim JY; Park JE; Jo Y; Shim WH; Nam SJ; Kim JH; Yoo RE; Choi SH; Kim HS
    Neuro Oncol; 2019 Feb; 21(3):404-414. PubMed ID: 30107606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glioblastoma pseudoprogression and true progression reveal spatially variable transcriptional differences.
    Wang W; Tugaoen JD; Fadda P; Toland AE; Ma Q; Elder JB; Giglio P; ; Otero JJ
    Acta Neuropathol Commun; 2023 Dec; 11(1):192. PubMed ID: 38049893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of multiparametric MRI based prediction model in identification of pseudoprogression in glioblastomas.
    de Godoy LL; Mohan S; Wang S; Nasrallah MP; Sakai Y; O'Rourke DM; Bagley S; Desai A; Loevner LA; Poptani H; Chawla S
    J Transl Med; 2023 Apr; 21(1):287. PubMed ID: 37118754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DC-AL GAN: Pseudoprogression and true tumor progression of glioblastoma multiform image classification based on DCGAN and AlexNet.
    Li M; Tang H; Chan MD; Zhou X; Qian X
    Med Phys; 2020 Mar; 47(3):1139-1150. PubMed ID: 31885094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review: Part 1 - Molecular, morphological and clinical features.
    Le Fèvre C; Lhermitte B; Ahle G; Chambrelant I; Cebula H; Antoni D; Keller A; Schott R; Thiery A; Constans JM; Noël G
    Crit Rev Oncol Hematol; 2021 Jan; 157():103188. PubMed ID: 33307200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression.
    Barajas RF; Hamilton BE; Schwartz D; McConnell HL; Pettersson DR; Horvath A; Szidonya L; Varallyay CG; Firkins J; Jaboin JJ; Kubicky CD; Raslan AM; Dogan A; Cetas JS; Ciporen J; Han SJ; Ambady P; Muldoon LL; Woltjer R; Rooney WD; Neuwelt EA
    Neuro Oncol; 2019 Mar; 21(4):517-526. PubMed ID: 30277536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.
    Strauss SB; Meng A; Ebani EJ; Chiang GC
    Radiol Clin North Am; 2019 Nov; 57(6):1199-1216. PubMed ID: 31582045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.